A randomized controlled trial of Human Papillomavirus (HPV) testing for cervicalcancer screening: trial design and preliminary results (HPV FOCAL Trial)
Authors:
- Gina S OgilvieGOGina S Ogilvie
- Dirk J van NiekerkDNDirk J van Niekerk
- Mel KrajdenMKMel Krajden
- Ruth E MartinRMRuth E Martin
- Thomas G EhlenTEThomas G Ehlen
- Kathy CeballosKCKathy Ceballos
- Stuart J PeacockStuart J Peacock
- Laurie W SmithLSLaurie W Smith
- Lisa KanLKLisa Kan
- Darrel A CookDCDarrel A Cook
- Wendy MeiWMWendy Mei
- Gavin Ce StuartGSGavin Ce Stuart
Open Access
- 24 March 2010
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 111
Abstract
In the HPV FOCAL trial, we will establish the efficacy of hr-HPV DNA testing as a stand-alone screening test followed by liquid based cytology (LBC) triage of hr-HPV-positive women compared to LBC followed by hr-HPV triage with ≥ CIN3 as the outcome. HPV-FOCAL is a randomized, controlled, three-armed study over a four year period conducted in British Columbia. It will recruit 33,000 women aged 25-65 through the province's population based cervical cancer screening program. Control arm: LBC at entry and two years, and combined LBC and hr-HPV at four years among those with initial negative results and hr-HPV triage of ASCUS cases; Two Year Safety Check arm: hr-HPV at entry and LBC at two years in those with initial negative results with LBC triage of hr-HPV positives; Four Year Intervention Arm: hr-HPV at entry and combined hr-HPV and LBC at four years among those with initial negative results with LBC triage of hr-HPV positive cases To date, 6150 participants have a completed sample and epidemiologic questionnaire. Of the 2019 women enrolled in the control arm, 1908 (94.5%) were cytology negative. Women aged 25-29 had the highest rates of HSIL (1.4%). In the safety arm 92.2% of women were hr-HPV negative, with the highest rate of hr-HPV positivity found in 25-29 year old women (23.5%). Similar results were obtained in the intervention arm HPV FOCAL is the first randomized trial in North America to examine hr-HPV testing as the primary screen for cervical cancer within a population-based cervical cancer screening program. International Standard Randomised Controlled Trial Number Register, ISRCTN79347302Keywords
This publication has 28 references indexed in Scilit:
- Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women—implications for vaccinationCancer Causes & Control, 2009
- Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for ScreeningObstetrics & Gynecology, 2004
- Management of women who test positive for high-risk types of human papillomavirus: the HART studyThe Lancet, 2003
- Chapter 13: Primary Screening of Cervical Cancer With Human Papillomavirus TestsJNCI Monographs, 2003
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- The 2001 Bethesda SystemTerminology for Reporting Results of Cervical CytologyJAMA, 2002
- Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection.2001
- Accuracy of the Papanicolaou Test in Screening for and Follow-up of Cervical Cytologic AbnormalitiesAnnals of Internal Medicine, 2000
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideThe Journal of Pathology, 1999
- Meta-analysis of Pap Test AccuracyAmerican Journal of Epidemiology, 1995